Stockscreener 앱 받기
4.88
5.24%
-0.27
시간 외 거래:
4.82
-0.06
-1.23%
Xeris Biopharma Holdings Inc 주식(XERS)의 최신 뉴스
AIGH Capital Management LLC Purchases 389,192 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - MarketBeat
Auto-Injectors Market Growth in Future Scope 2025-2032 | Sanofi - openPR
Xeris Pharmaceuticals Announces Board Changes with New Appointment - TipRanks
Xeris Announces Changes To Its Board Of Directors - MarketScreener
Xeris Biopharma reshuffles board, appoints new director - Investing.com
Xeris Biopharma reshuffles board, appoints new director By Investing.com - Investing.com Australia
Xeris Announces Changes to Its Board of Directors - Business Wire
Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5? - Insider Monkey
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Sold by Bank of New York Mellon Corp - Defense World
Don't Ignore The Insider Selling In Xeris Biopharma Holdings - simplywall.st
Connor Clark & Lunn Investment Management Ltd. Has $581,000 Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma (NASDAQ:XERS) Stock Price Up 4.9% – Here’s Why - Defense World
Xeris Biopharma chief legal officer Beth Hecht sells $217,244 in stock - Investing.com Australia
Xeris Biopharma chief legal officer Beth Hecht sells $217,244 in stock By Investing.com - Investing.com South Africa
Xeris Pharmaceuticals stock hits 52-week high at $5.54 - Investing.com
Xeris Pharmaceuticals stock hits 52-week high at $5.54 By Investing.com - Investing.com South Africa
Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength? - Yahoo Finance
Xeris Biopharma (NASDAQ:XERS) Reaches New 52-Week High – Time to Buy? - Defense World
Xeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market Game - Insider Monkey
Xeris enters a whole new market for one of its main pharma offerings - Crain's Chicago Business
Is XERS Stock a Good Buy in 2025? Key Insights for Investors - Stocks Telegraph
12 Best Stocks to Invest in for a Stock Market Game - Insider Monkey
Xeris Biopharma gets FDA nod for Gvoke VialDx, teams with American Regent - Investing.com Australia
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid - BioSpace
Xeris Biopharma Says US FDA Approves Gvoke VialDx for Diagnostic Use -March 17, 2025 at 08:33 am EDT - Marketscreener.com
Xeris Biopharma gets FDA nod for Gvoke VialDx, teams with American Regent By Investing.com - Investing.com South Africa
Breakthrough FDA Approval: Xeris' Novel Glucagon Solution Transforms Radiologic Diagnostics - Stock Titan
Xeris Biopharma: Low Risk, Low Excitement Solid Revenue Generator (NASDAQ:XERS) - Seeking Alpha
Investors Appear Satisfied With Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Prospects As Shares Rocket 34% - Simply Wall St
Xeris BiopharmaPossibly the best Pharma Stock - MSN
Analysts Set Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Target Price at $5.92 - Defense World
Will Xeris Biopharma's Financial Transformation Reach New Heights In 2025? - RTTNews
Xeris Biopharma (XERS) Expects to Ride the Wave of 30% Revenue Growth in 2025 - Markets Insider
What Are Expectations For Xeris Biopharma Holdings Inc (NASDAQ: XERS) In The Short Term? - Stocks Register
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2024 Earnings Call Transcript - Insider Monkey
Analysts Issue Forecasts for Xeris Biopharma Q1 Earnings - Defense World
Piper Sandler Reaffirms Neutral Rating for Xeris Biopharma (NASDAQ:XERS) - Defense World
HC Wainwright Reaffirms Buy Rating for Xeris Biopharma (NASDAQ:XERS) - Defense World
Who Really Controls Xeris Biopharma? The Retail Investors’ Unseen Power - DSA
Principal Financial Group Inc. Grows Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Rhumbline Advisers Purchases 7,408 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings Inc (XERS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ... - Yahoo Finance
Xeris Biopharma Holdings Inc (XERS) Q4 2024 Earnings Call Highli - GuruFocus.com
Xeris Biopharma Reports Record Revenue and Strong 2025 Outlook - TipRanks
Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In - MSN
Xeris Biopharma Holdings Inc. (XERS) reports earnings - Quartz
1.23%
1.63%
자본화:
|
볼륨(24시간):